PHOENIX, Arizona—March 22, 2015
Arizona Heart Rhythm Center(AZHRC) now has the largest patient enrollment of the 50 US sites studying the use of multi-electrode, open irrigation nMARQ Pulmonary Vein Isolation System™ to treat paroxysmal Atrial Fibrillation (A Fib) as part of the reMARQable clinical study.
“We are really encouraged by the early results from this new system,” said Dr. Vijay Swarup, M.D., F.A.C.C., F.H.R.S., cardiac electrophysiologist and medical director of AZHRC, who performed most of procedures. “It is another promising tool to effectively treat patients with Atrial Fibrillation.”
A Fib is a heart rhythm disorder that affects approximately 5 million Americans and 15 million people worldwide. During A Fib, the heart’s upper chambers beat rapidly or quiver instead of beating effectively. Because of this blood may stagnate in the atria, causing formation of a clot. If this clot dislodges and travels to the brain, a stroke can occur. Atrial Fibrillation increases the risk of stroke 5 folds and is often associated with disabling symptoms of palpitations, shortness of breath and fatigue. If untreated it can also cause weakness of heart muscle leading to heart failure.
The reMARQable study is designed to evaluate the safety and effectiveness of the use of the nMARQ Pulmonary Vein Isolation System to treat A Fib. During ablation, physicians isolate pulmonary veins—the primary drivers of A Fib—from the rest of the heart. Doctors then use catheters to deliver energy to portions of the veins to create scars, or lesions, to prevent the abnormal signals that cause A Fib from reaching the atrium. The nMARQ system consists of a multi-electrode, irrigated catheter ablation system, which may allow for faster, more effective isolation of the pulmonary veins.
Traditionally, physicians create multiple single ablations to form a line of lesions. This process sometimes leaves gaps which is an important cause of AFib recurrence. The nMARQ catheters are designed to create long continuous linear lesions in one application. Additionally, the irrigated catheters increase safety by cooling the electrodes, preventing a condition known as char formation thereby reducing the risk of intra procedure stroke.
The nMARQ Pulmonary Vein Isolation System, manufactured by Biosense Webster, Inc., has not yet received approval by the U.S. Food and Drug Administration for use outside this clinical trial. AZHRC is one of up to 50 sites in the country participating in this Investigational Device study.
The Arizona Heart Rhythm Center is among the world’s leading diagnostic and treatment center for patients with all types of heart rhythm conditions, including atrial fibrillation.
Arizona Heart Rhythm Center
500 W. Thomas Road, Suite 750
Phoenix, AZ 85013